发明名称 |
Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
摘要 |
A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.; |
申请公布号 |
US9205086(B2) |
申请公布日期 |
2015.12.08 |
申请号 |
US201113642068 |
申请日期 |
2011.04.19 |
申请人 |
Synta Pharmaceuticals Corp. |
发明人 |
Blackman Ronald K.;Foley Kevin Paul;Proia David |
分类号 |
A61K31/44;A61K31/517;A61K31/4196;A61K31/675 |
主分类号 |
A61K31/44 |
代理机构 |
McCarter & English, LLP |
代理人 |
McCarter & English, LLP ;Davis Steven G. |
主权项 |
1. A method of treating non small cell lung cancer in a mammal, comprising administering to the mammal an effective amount of an compound, which is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of an EGFR inhibitor, wherein, the EGFR inhibitor is erlotinib and the effective amount of the compound and the effective amount of the EGFR inhibitor together results in a synergistic effect against the non-small cell lung cancer. |
地址 |
Lexington MA US |